BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 7252843)

  • 1. Antihypertensive and hemodynamic actions of SCH 19927, the R,R-isomer and labetalol.
    Baum T; Watkins RW; Sybertz EJ; Vemulapalli S; Pula KK; Eynon E; Nelson S; Vliet GV; Glennon J; Moran RM
    J Pharmacol Exp Ther; 1981 Aug; 218(2):444-52. PubMed ID: 7252843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antihypertensive actions of an isomer of labetalol and other vasodilator-beta-adrenoceptor blockers.
    Baum T; Sybertz EJ
    Fed Proc; 1983 Feb; 42(2):176-81. PubMed ID: 6130003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the animal pharmacology of labetalol, a combined alpha- and beta-adrenoceptor-blocking drug.
    Brittain RT; Levy GP
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):681-4. PubMed ID: 10948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha and beta adrenoceptor blocking properties of labetalol and its R,R-isomer, SCH 19927.
    Sybertz EJ; Sabin CS; Pula KK; Vliet GV; Glennon J; Gold EH; Baum T
    J Pharmacol Exp Ther; 1981 Aug; 218(2):435-43. PubMed ID: 6114171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the R, R-isomer of labetalol, SCH 19927, in isolated tissues and in spontaneously hypertensive rats during a repeated treatment.
    Monopoli A; Bamonte F; Forlani A; Ongini E; Parravicini L
    Arch Int Pharmacodyn Ther; 1984 Dec; 272(2):256-63. PubMed ID: 6151824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic effects of labetalol in the dog. Comparative study in the anesthetized open-chest dog and in the conscious dog.
    Saito D; Abe Y; Tani H; Kusachi S; Takeda K; Hyodo T; Haraoka S; Nagashima H
    Arzneimittelforschung; 1986; 36(1):88-91. PubMed ID: 2869764
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac electrophysiologic actions of SCH 19927 (Dilevalol), the R,R-isomer of labetalol.
    Lynch JJ; Montgomery DG; Lucchesi BR
    J Pharmacol Exp Ther; 1986 Dec; 239(3):719-23. PubMed ID: 3795037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of beta 2-receptor stimulation in the peripheral vascular actions of the antihypertensive dilevalol.
    Watkins RW; Sybertz EJ; Cook J; Pula K; Cedeno K; Tedesco RP; McLeod R
    Arch Int Pharmacodyn Ther; 1989; 302():158-73. PubMed ID: 2576892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and comparison of some cardiovascular properties of the stereoisomers of labetalol.
    Gold EH; Chang W; Cohen M; Baum T; Ehrreich S; Johnson G; Prioli N; Sybertz EJ
    J Med Chem; 1982 Nov; 25(11):1363-70. PubMed ID: 6128421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Haemodynamic effects of long-term oral labetalol.
    Edwards RC; Raftery EB
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):733-6. PubMed ID: 791328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha- and beta-adrenoceptor blocking properties of labetalol in renin release.
    Lammintausta R; Koulu M; Allonen H
    Int J Clin Pharmacol Biopharm; 1979 Jun; 17(6):240-43. PubMed ID: 38214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive, hemodynamic and autonomic profile of a new angiotensin converting enzyme inhibitor, SCH 33844 (spirapril).
    Baum T; Watkins RW; Sybertz EJ; Ahn HS; Nelson S; Coleman W; Tedesco R; Pula KK; Rivelli M; Sabin C
    Arch Int Pharmacodyn Ther; 1987 Apr; 286(2):230-45. PubMed ID: 2884941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effects of labetalol on the circulatory system (author's transl)].
    Monma Y; Okuoka Y; Kameda H; Ichihara K; Abiko Y; Tanabe T
    Nihon Yakurigaku Zasshi; 1980 May; 76(4):239-54. PubMed ID: 6108907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of labetalol in producing deliberate hypotension and its effects on intracranial pressure in dogs.
    Van Aken H; Puchstein C; Hidding J
    Acta Anaesthesiol Belg; 1982; 33(1):5-12. PubMed ID: 7090725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antihypertensive effects of labetalol in three types of hypertensive models of rats (author's transl)].
    Nakagawa Y; Takeda K; Sakurai H; Mitomi A; Imai S
    Nihon Yakurigaku Zasshi; 1981 Apr; 77(4):435-45. PubMed ID: 7286847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular properties of medroxalol, a new antihypertensive drug.
    Dage RC; Cheng HC; Woodward JK
    J Cardiovasc Pharmacol; 1981; 3(2):299-315. PubMed ID: 6166802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of an alpha- and beta-adrenoceptor-blocking agent (labetalol) on haemodynamics in hypertension.
    Bahlmann J; Brod J; Hubrich W; Cachovan M; Pretschner P
    Br J Clin Pharmacol; 1979; 8(Suppl 2):113S-117S. PubMed ID: 526390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic, pulmonary and coronary haemodynamic actions of the novel dopamine receptor agonist in awake pigs at rest and during treadmill exercise Z1046.
    Duncker DJ; Haitsma DB; van der Geest IE; Stubenitsky R; van Meegen JR; Man in't Veld AJ; Verdouw PD
    Br J Pharmacol; 1997 Mar; 120(6):1101-13. PubMed ID: 9134223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular effects of a novel vasoactive antihypertensive agent, Ro 12-4713.
    Gerold M; Eigenmann R; Hefti F; Daum A; Haeusler G
    J Pharmacol Exp Ther; 1981 Mar; 216(3):624-33. PubMed ID: 7009831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular effects of labetalol during halothane anaesthesia.
    Scott DB; Buckley FP; Drummond GB; Littlewoods DG; Macrae WR
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):817-21. PubMed ID: 990159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.